There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Phasebio Pharmaceuticals (PHAS – Research Report) and TFF Pharmaceuticals (TFFP – Research Report) with bullish sentiments.
Phasebio Pharmaceuticals (PHAS)
In a report released today, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Phasebio Pharmaceuticals, with a price target of $8.00. The company’s shares closed last Thursday at $3.94.
According to TipRanks.com, Archila is a 4-star analyst with an average return of 8.0% and a 46.6% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Apellis Pharmaceuticals.
Currently, the analyst consensus on Phasebio Pharmaceuticals is a Strong Buy with an average price target of $14.00.
TFF Pharmaceuticals (TFFP)
In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on TFF Pharmaceuticals, with a price target of $31.00. The company’s shares closed last Thursday at $11.26.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 27.8% and a 57.0% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Frequency Therapeutics.
TFF Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $29.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.